Mergers: Commission approves acquisition of Bard by BD, subject to conditions

 The Commission has conditionally approved, under the EU Merger Regulation, the acquisition of Bard by BD. Both companies supply medical devices. The companies' activities are largely complementary but overlap in the markets for core needle biopsy devices and tissue markers, which are both used for the diagnosis of medical conditions such as breast cancer. The Commission examined the competitive effects of the proposed acquisition on the core needle biopsy devices and tissue markers. In order to address the Commission's concerns in these markets, BD committed to divest its: i) worldwide core needle biopsy business, including manufacturing equipment, finished goods inventory, and intangible assets required to produce the core needle biopsy products, and ii) development projects related to core needle biopsy products and tissue markers.  The Commission found that the proposed transaction, as modified by the commitments, would not raise competition concerns. Commissioner Margrethe Vestager, in charge of competition policy, said: "The conditions we have imposed on this merger will help to ensure that millions of European patients and Member States' healthcare systems in the EU, will continue to enjoy access at fair prices to a variety of innovative medical devices – in this case devices that are key to diagnose and treat very serious medical conditions, such as cancer." A full press release is available in ENDEFR.

© Copyright 2010-16 Invest in EU All rights reserved.